GlassScriptPhysician profile
Bethany R Troutwine
NPI 1740509801
$856.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $267.12 | 2019-2020 | |
| Lilly USA, LLC | $168.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $76.72 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $61.94 | 2019 | |
| Astellas Pharma US INC | $57.29 | 2019-2020 | |
| Allergan, INC. | $46.56 | 2019-2020 | |
| Novo Nordisk INC | $35.46 | 2019-2020 | |
| Abbvie INC. | $26.85 | 2019 | |
| Tris Pharma INC | $25.88 | 2019 | |
| Merck Sharp & Dohme LLC | $24.04 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.97 | 2019 | |
| Sanofi Pasteur INC. | $11.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.46 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Troutwine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.